Nanostructured Lipid Carriers A Novel Platform for Chemotherapeutics

Purpose: Conventional cancer chemotherapy suffers from poor drug specificity, narrow therapeutic windows, high dose-limiting toxicity, and multidrug resistance (MDR). Nanostructured lipid carriers (NLCs) are biocompatible, biodegradable lipid-based nanoparticles that can improve solubility, stability, targeting, and controlled release of chemotherapeutics, potentially overcoming limitations of solid lipid nanoparticles (SLNs) and conventional delivery systems.

Hypothesis: If anticancer drugs, genes, or imaging agents are incorporated into NLCs composed of optimized solid and liquid lipids with suitable surfactants and surface modifications, then NLCs can improve drug loading, stability, tumor-specific targeting, MDR reversal, gene delivery, and theranostic performance while reducing systemic toxicity.

Aims: Review NLC composition, excipient selection, types, and preparation methods. - Analyze factors influencing NLC formulation, including lipids, surfactants, HLB, temperature, stirring, and technique. - Summarize characterization parameters and drug release behavior. - Discuss obstacles in tumor drug delivery and strategies to enhance anticancer activity through passive targeting, active targeting, PEGylation, MDR reversal, gene delivery, and theranostics. - Highlight applications of NLCs in cancer chemotherapy by different administration routes.

Delivery system: Platform: nanostructured lipid carriers (NLCs), composed of a solid lipid matrix blended with liquid lipids and stabilized by surfactants/emulsifiers. - Payloads: chemotherapeutic drugs, genes (DNA, siRNA), imaging agents, and theranostic combinations. - Key excipients: solid lipids (e.g., Compritol 888 ATO, Precirol ATO 5, stearic acid, cetyl palmitate, glyceryl monostearate, tripalmitin); liquid lipids (e.g., oleic acid, Miglyol 812, squalene, isopropyl myristate, soybean oil, Labrafac); surfactants (Tween 80, Poloxamer 188, Cremophor EL, Solutol HS 15, lecithin, Span 40). - Targeting/functionalization: folate, hyaluronic acid, transferrin, monoclonal antibodies, aptamers, peptides (e.g., CREKA, LHRH), VEGFR-2 antibody, stearyl-2-amino-2-deoxyglucose, and PEGylation. - Preparation methods: high-pressure homogenization (hot/cold), high-shear homogenization/ultrasonication, microemulsion, solvent emulsification-evaporation, solvent emulsification-diffusion, solvent injection, W/O/W double emulsion, phase inversion, membrane contactor. - Administration routes discussed: oral, parenteral, inhalational, topical, and intranasal.

Approach: Review and synthesis of preclinical literature. In vitro models include MCF-7, A549, HepG2, Caco-2, K562, U87MG, B16, HCT116, and others. In vivo models include mice, rats, nude mice, and tumor-bearing models such as H22, B16F10, A549 xenografts, and Ehrlich’s ascites tumor allografts. Disease context is mainly cancer. As a review, it reports no primary experimental groups, n values, doses, or controls.

Key methods: No primary methods. The review discusses data generated by cited studies using: - Particle size and PDI by photon correlation spectroscopy (PCS) and laser diffraction. - Zeta potential measurement. - SEM, TEM, AFM for shape and morphology. - DSC and XRD for crystallinity and polymorphism. - In vitro drug release and release kinetics modeling. - Cytotoxicity (IC50), cell viability, cellular uptake, and transfection assays. - In vivo biodistribution, pharmacokinetics, antitumor efficacy, and toxicity assessments. - Imaging and theranostic evaluation.

Key results: PTX–DOX co-loaded NLCs had a mean size of 129.3 ± 4.2 nm and showed excellent cytotoxicity in NCI-H460 cells and in a human NSCLC xenograft model. - Curcumin NLCs (~214 nm) enhanced brain tumor inhibitory efficiency to 90% compared with free drug solution. - Transferrin-conjugated etoposide NLCs showed a 15-fold reduction in IC50 versus free etoposide in K562 acute myelogenous leukemia cells. - Baicalein-loaded tocol NLCs after IV injection produced 7.5-fold higher AUC in the cortex, 4.7-fold in the brain stem, and 2–3-fold increases in hippocampus, thalamus, and striatum. - Paclitaxel–doxorubicin NLCs showed reversal power of 34.3- and 31.3-fold for paclitaxel NLCs and 6.4- and 2.2-fold for doxorubicin NLCs in resistant cancer cell lines. - PEGylated 10-hydroxycamptothecin NLCs showed a 40-fold improvement in maximum drug concentration in lungs versus free drug solution. - Biochanin A PEGylated NLCs showed approximately 15.8- and 2.9-fold higher Cmax and AUC than free drug and longer mean residence time. - Theranostic camptothecin/quantum dot NLCs showed 6.4-fold higher camptothecin accumulation and enhanced cytotoxicity in B16-F0 melanoma cells; CREKA-peptide NLCs showed 3-fold higher binding and ~40-fold greater movement in tumor vasculature. - Gene delivery: Tf-PTX-DNA-NLCs reduced IC50 by more than 4-fold versus paclitaxel solution; TMZ/DNA-NLCs reduced IC50 by more than 4-fold versus TMZ and showed 3.3-fold higher tumor inhibition in glioma xenografts.

Interpretation: The authors conclude that NLCs are a promising nanoplatform for cancer chemotherapy. They can improve hydrophobic drug solubility, provide controlled release, bypass P-gp-mediated efflux, enable passive and active tumor targeting, support gene delivery, and serve as theranostic carriers. NLCs are considered versatile, scalable, and potentially safer than some polymeric carriers, with opportunities to overcome MDR and improve chemotherapy outcomes.

Limitations: Review article; no primary data, effect sizes, n values, doses, or controls. - NLCs still face challenges in long-term stability, drug expulsion during storage, and scale-up. - Surfactant and emulsifier toxicity, especially at higher concentrations, remains a concern. - Passive targeting relies on the EPR effect and is limited by tumor heterogeneity and high interstitial fluid pressure. - Active targeting can be compromised by rapid RES clearance before tumor binding. - MDR is complex and involves multiple efflux pumps, enzymes, and microenvironment factors. - Clinical translation is limited; most evidence is preclinical. - Standardized characterization and regulatory pathways for NLC-based chemotherapeutics are still evolving.